Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03441113 · ClinicalTrials.gov registry record · Phase 2
Extended Access of Momelotinib in Adults With Myelofibrosis
A Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF), sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
- 20
- Study locations
NCT03441113: Active Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF), sponsored by GlaxoSmithKline.
NCT03441113 is a Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF) that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 237 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03441113, a Phase 2 study of Neoplasms and Primary Myelofibrosis (PMF), is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease. The secondary objective is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.
Conditions Studied
Interventions
- DRUG MMB
Study Locations (20)
Florida
- GSK Investigational Site - Jacksonville
- Mayo Clinic Florida - Jacksonville
- GSK Investigational Site - Tampa
- Moffitt Cancer Center - Tampa
California
- IC Irvine Health - Orange
- GSK Investigational Site - Stanford
- Stanford Hospital and Clinics - Stanford
Colorado
- GSK Investigational Site - Aurora
- University of Colorado Cancer Center - Aurora
Georgia
- GSK Investigational Site - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Maryland
- GSK Investigational Site - Baltimore
- Saint Agnes Hospital - Baltimore
Massachusetts
- Dana-Farber Cancer Institute (DFCI) - Boston
- GSK Investigational Site - Boston
Minnesota
- GSK Investigational Site - Rochester
- Mayo Clinic - Department of Hematology - Rochester
Missouri
- Washington University School of Medicine Siteman Cancer Center - St Louis
- GSK Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03441113 still lists
NCT03441113 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which MMB is the first listed.
NCT03441113 names 20 study sites across 9 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03441113 about?
NCT03441113 is a clinical study titled "Extended Access of Momelotinib in Adults With Myelofibrosis". The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT0196983...
What is the current status of trial NCT03441113?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2018-05-03. Estimated completion is 2026-12-31.
What conditions does trial NCT03441113 study?
This clinical trial studies the following conditions: Neoplasms, Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF).
What interventions are being tested in trial NCT03441113?
The interventions under investigation include: MMB (DRUG).
Who is sponsoring clinical trial NCT03441113?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03441113 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03441113's enrollment target sits among peer trials
237 41st of 158 higher than 118 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI